Amundi
BMRN icon

Amundi’s BioMarin Pharmaceuticals BMRN Stock Holding History

Amundi’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
259,782
+71,246
+38% +$3.9M ﹤0.01% 827
2026
Q1 		$10.7M Sell
188,536
-9,047
-5% -$527K ﹤0.01% 872
2025
Q4 		$11.7M Sell
197,583
-515,304
-72% -$28.1M ﹤0.01% 915
2025
Q3 		$39.6M Buy
712,887
+145,272
+26% +$8.31M 0.01% 611
2025
Q2 		$32.5M Buy
567,615
+161,936
+40% +$9.54M 0.01% 632
2025
Q1 		$27.4M Buy
405,679
+6,441
+2% +$433K 0.01% 656
2024
Q4 		$27.3M Buy
399,238
+88,247
+28% +$5.91M 0.01% 666
2024
Q3 		$21.4M Sell
310,991
-36,006
-10% -$3.01M 0.01% 703
2024
Q2 		$28.1M Sell
346,997
-97,123
-22% -$8.09M 0.01% 641
2024
Q1 		$40M Buy
444,120
+68,910
+18% +$6.17M 0.02% 567
2023
Q4 		$36.1M Sell
375,210
-397,780
-51% -$35.2M 0.02% 598
2023
Q3 		$66.7M Buy
772,990
+341,737
+79% +$30.4M 0.03% 441
2023
Q2 		$37M Sell
431,253
-736,068
-63% -$69.3M 0.02% 579
2023
Q1 		$113M Sell
1,167,321
-506,372
-30% -$52.5M 0.06% 326
2022
Q4 		$186M Sell
1,673,693
-70,739
-4% -$6.64M 0.1% 227
2022
Q3 		$156M Buy
1,744,432
+1,448,878
+490% +$129M 0.09% 241
2022
Q2 		$25.6M Buy
295,554
+34,039
+13% +$2.71M 0.02% 576
2022
Q1 		$21.8M Buy
261,515
+111,623
+74% +$9.34M 0.01% 638
2021
Q4 		$13.2M Buy
149,892
+3,984
+3% +$329K 0.01% 776
2021
Q3 		$11.3M Buy
145,908
+7,933
+6% +$626K 0.01% 815
2021
Q2 		$11.5M Buy
+137,975
New +$10.9M 0.01% 801

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Amundi's BMRN Position: Q2 2026 in Review

Amundi increased its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q2 2026, buying an estimated $3.9M and bringing the position to 259,782 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #827.

Amundi first reported a position in BMRN in Q2 2021 and has held it in 21 quarters since. The position peaked at $186M in Q4 2022. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Amundi held 259,782 shares of BioMarin Pharmaceuticals worth $14.9M as of Q2 2026.
  • Amundi bought 71,246 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.9M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #827 holding.
  • Amundi first reported a position in BioMarin Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Amundi's BioMarin Pharmaceuticals position peaked at $186M in Q4 2022.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.